statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

XPOVIO (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country

XPOVIO (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country XPOVIO (selinexor) Approved for New Indication in DLBCL in China, Bringing...

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire NEWTON...

Antengene Announces XPOVIO (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea

Antengene Announces XPOVIO (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea Antengene Announces XPOVIO (selinexor) National Health Insurance Service Approval...

Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates

Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract...

Karyopharm to Participate at the Jefferies Global Healthcare Conference

Karyopharm to Participate at the Jefferies Global Healthcare Conference Karyopharm to Participate at the Jefferies Global Healthcare Conference PR Newswire NEWTON, Mass., May 29, 2024 NEWTON, Mass...

Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference

Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference PR Newswire NEWTON...

Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029

Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029 Karyopharm Announces Significant Refinancing...

Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress PR...

Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024

Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024 Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024 PR Newswire NEWTON, Mass., May 2, 2024 -- Conference...

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

Volume	1.67M
52-Wk High	$1.95
52-Wk Low	$0.6174

KPTI Karyopharm Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals